Consent given pursuant to sections 14 and 14A for the supply and importation of the Therapeutic Goods specified subject to conditions specified - Emerge Health Pty Ltd

Overview

The Therapeutic Goods Act 1989 is a key piece of legislation enacted to ensure the safety, quality, and efficacy of therapeutic goods in Australia. This Act was introduced to address the critical need for stringent regulation and oversight of therapeutic goods, encompassing medicines, medical devices, and other related products. Enacted by the Commonwealth Parliament, the Act establishes a comprehensive framework to govern the manufacture, importation, supply, and advertising of therapeutic goods, thereby protecting public health. The policy objective of the Act is to safeguard the health and safety of Australians by ensuring that therapeutic goods meet high standards before they are made available in the market. The Therapeutic Goods Administration, under the Department of Health, is the body responsible for enforcing the provisions of the Act, ensuring compliance through rigorous assessment and monitoring processes.

Scope and Application

The Therapeutic Goods Act 1989 applies to the regulation of therapeutic goods in Australia, encompassing a broad range of products including medicines, medical devices, blood and tissues. The Act applies to persons and entities involved in the supply, manufacture, importation, exportation, and advertising of therapeutic goods, ensuring that these goods meet required safety, quality, and efficacy standards. The application of the Act extends across the Commonwealth, thereby providing a unified regulatory framework for therapeutic goods throughout Australia. Notably, the Act also extends its reach through subordinate legislation and regulations, which further detail the specific requirements and conditions under which therapeutic goods must be handled and marketed. There are certain exclusions and exemptions within the Act, such as those for goods used for personal, non-commercial purposes, or those supplied under specific conditions like research or clinical trials, which are regulated under particular provisions of the Act and related orders. The specific case concerning Emerge Health Pty Ltd and the importation and supply of poractant alfa (CUROSURF) vials illustrates an application of the Act's provisions for granting consents under section 14 and 14A. This consent allows for the temporary deviation from standard labelling requirements, specifically concerning the inclusion of the former sponsor's details on the vial labels. The consent is tightly controlled, applying only to a defined quantity of vials and subject to specific conditions aimed at ensuring continuity of medical support and adverse event reporting. This case highlights the Act's flexibility in accommodating exceptional circumstances while maintaining the overarching objective of protecting public health.

Key Provisions

Under the Therapeutic Goods Act 1989, specifically sections 14 and 14A, the Secretary of the Department of Health granted Emerge Health Pty Ltd consent to import and supply two types of poractant alfa (CUROSURF) vials that do not fully comply with the labelling requirements outlined in the Therapeutic Goods Order No. 69. Despite the non-compliance, the consent allows for the import and supply of these vials, which are intended for intratracheal use in treating respiratory distress syndrome in neonates. The specific non-compliance pertains to the inclusion of the former sponsor’s (Ascent) name and contact details on the vial labels, which deviates from the prescribed labelling requirements. The consent, effective from September 25, 2014, remains in place until further notice and is limited to a specific quantity of vials, 364 of the 120 mg/1.5 mL type and 485 of the 240 mg/3 mL type, representing the stock available as of September 15, 2014. The Therapeutic Goods Act 1989 imposes several obligations on Emerge Health Pty Ltd as the recipient of this consent. They are required to ensure that appropriate processes are in place to manage medical inquiries and adverse event reports. This includes setting up a system to receive and triage such information, initially handling it through the former sponsor, Ascent, before forwarding it to Emerge Health for further action. This obligation underscores the importance of maintaining effective communication and reporting mechanisms to ensure patient safety and compliance with therapeutic goods regulations. Failure to comply with the conditions outlined in the consent or the broader requirements of the Therapeutic Goods Act 1989 may result in significant legal and financial repercussions. Under section 15 of the Act, any breach of the consent conditions could lead to enforcement actions by the Department of Health. The potential consequences include fines, legal penalties, and in severe cases, the revocation of the consent, which would halt the importation and supply of the therapeutic goods in question. The Act does not specify maximum penalties for breaches of consent conditions, but general provisions within the Act allow for substantial fines and other penalties for non-compliance with therapeutic goods regulations. The Therapeutic Goods Act 1989 provides a framework for regulating the importation, supply, and use of therapeutic goods in Australia. By granting this specific consent under sections 14 and 14A, the Department of Health has outlined clear conditions to mitigate any risks associated with the non-compliant labelling of the poractant alfa vials. This approach ensures that while the therapeutic benefits of these products can be made available, the regulatory standards for safety and quality are upheld as closely as possible. Compliance with these conditions and the Act’s broader requirements is crucial for ensuring that therapeutic goods meet the necessary standards for use in Australia.